ICD-10 C71.2 is officially defined as "Malignant neoplasm of temporal lobe." code C71.2 is referenced in 7 tracked payer policy changes from Blue Cross Blue Shield of Rhode Island, Health Net, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code C71.2 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Multiple policy updates are rolling out between February-April 2026, including InterQual criteria changes for molecular diagnostics and procedures, fertility coverage modifications, removal of prior authorization for several genetic testing and continuous glucose monitoring codes, and updated diagnosis code lists for various services.
Health Net updated multiple medical policies in Q4 2020, affecting prior authorization requirements, coverage criteria, and billing codes across numerous specialties including oxygen therapy, allergy testing, bariatric surgery, wound care, and various diagnostic procedures.
CalViva Health updated multiple medical policies for Q4 2020 affecting prior authorization requirements, coverage criteria, and billing codes across numerous specialties. Key changes include revised oxygen therapy criteria, new ambulatory surgery center redirection requirements, updated bariatric surgery protocols, and modified coverage for various diagnostic and therapeutic services.
Independence Blue Cross reissued Policy 07.03.26b on Tumor Treating Fields (TTFields) for glioblastoma treatment, adding CPT code 1025T (dosimetry and delivery simulation) as medically necessary effective 01/01/2026. The policy covers TTFields for newly diagnosed glioblastoma with adjuvant temozolomide and recurrent glioblastoma as monotherapy in adult patients meeting specific clinical criteria. Billing teams must ensure claims for TTFields therapy include proper documentation and use the correct HCPCS code E0766 for device reimbursement.
Independence Blue Cross reissued Policy 07.03.26b on Tumor Treating Fields (TTFields) effective 01/01/2026, adding CPT code 1025T for dosimetry and simulation modeling as medically necessary. This is a minor update to communicate the company's continuing position; coverage criteria for newly diagnosed and recurrent glioblastoma remain unchanged, but billing teams must now recognize 1025T as a separately billable service.
Aetna considers interstitial laser therapy medically necessary for refractory epilepsy when the criteria in CPB 0394 - Epilepsy Surgery are met. It also considers it medically necessary for persons with recurrent brain metastases, recurrent glioblastoma, or radiation necrosis who are poor surgical candidates for craniotomy and resection, where open surgery presents prohibitive surgical risk or the tumor is located at a surgically inaccessible site. Aetna considers interstitial laser therapy experimental, investigational, or unproven for many other indications, including breast tumors, liver metastases, lung cancer, prostate cancer, pancreatic cancer, thyroid nodules, tremor disorders and chronic intractable non-malignant pain.
Aetna re-reviewed its Interstitial Laser Therapy policy (CPB 0781) on October 30, 2026, but the page does not say what changed or give a new effective date. As written, the policy covers laser ablation (LITT) only for certain intractable epilepsy cases and for recurrent brain tumors, radiation necrosis or metastases in poor surgical candidates, and treats it as experimental for most other sites, including breast, thyroid, lung, liver, prostate and spine.
Watch C71.2
Get one email when a payer policy names C71.2, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.